KNTPF (Kintor Pharmaceutical) ROC %: -46.26% (As of Dec. 2025)


KNTPF Kintor Pharmaceutical Ltd KNTPF
20 GF Score
Price $0.34
! 3 Warning Signs
View Full Analysis

What is Kintor Pharmaceutical ROC %?

Kintor Pharmaceutical KNTPF 20 ROC % is -46.26% as of Dec. 2025. GuruFocus rates KNTPF with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Kintor Pharmaceutical's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -46.26%.

As of today (2026-06-29), Kintor Pharmaceutical's WACC % is 15.81%. Kintor Pharmaceutical's ROC % is -41.68% (calculated using TTM income statement data). Kintor Pharmaceutical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Kintor Pharmaceutical  (OTCPK:KNTPF) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Kintor Pharmaceutical's WACC % is 15.81%. Kintor Pharmaceutical's ROC % is -41.68% (calculated using TTM income statement data). Kintor Pharmaceutical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Kintor Pharmaceutical ROC % Related Terms


Kintor Pharmaceutical ROC % Historical Data

* Premium members only.

The historical data trend for Kintor Pharmaceutical's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kintor Pharmaceutical ROC % Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial -127.83 -105.10 -140.71 -31.21 -42.05

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -222.27 -26.64 -32.57 -37.38 -46.26
KNTPF
20GF Score
Kintor Pharmaceutical Ltd KNTPF
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kintor Pharmaceutical ROC % Calculation

Kintor Pharmaceutical's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-24.606 * ( 1 - 1.41% )/( (62.686 + 52.699)/ 2 )
=-24.2590554/57.6925
=-42.05 %

where

Kintor Pharmaceutical's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-26.152 * ( 1 - 2.16% )/( (57.927 + 52.699)/ 2 )
=-25.5871168/55.313
=-46.26 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -46.26% mean?
Kintor Pharmaceutical (KNTPF) has a ROC % of -46.26% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Kintor Pharmaceutical and its competitors.
Is Kintor Pharmaceutical's ROC % too high?
Kintor Pharmaceutical's current ROC % is -46.26%. Overall, Kintor Pharmaceutical has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's ROC % compare to VRTX and REGN?
Kintor Pharmaceutical's ROC % of -46.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Kintor Pharmaceutical and its competitors. Kintor Pharmaceutical's current ROC % is -46.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current ROC % of -46.26%. The current ROC % is -46.26%. Kintor Pharmaceutical's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current ROC % is -46.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kintor Pharmaceutical Business Description

Other Exchanges 09939:Hong Kong
Address No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
20GF Score

Get the complete analysis for KNTPF

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price